Zimmer Biomet/$ZBH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zimmer Biomet
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Ticker
$ZBH
Sector
Primary listing
NYSE
Employees
17,000
Headquarters
Website
Zimmer Biomet Metrics
BasicAdvanced
$20B
24.99
$4.11
0.68
$0.96
0.93%
Price and volume
Market cap
$20B
Beta
0.68
52-week high
$114.44
52-week low
$89.22
Average daily volume
1.3M
Dividend rate
$0.96
Financial strength
Current ratio
1.872
Quick ratio
0.803
Long term debt to equity
54.838
Total debt to equity
61.603
Dividend payout ratio (TTM)
23.38%
Interest coverage (TTM)
5.91%
Profitability
EBITDA (TTM)
2,590.4
Gross margin (TTM)
71.25%
Net profit margin (TTM)
10.51%
Operating margin (TTM)
19.76%
Effective tax rate (TTM)
15.17%
Revenue per employee (TTM)
$460,000
Management effectiveness
Return on assets (TTM)
4.36%
Return on equity (TTM)
6.53%
Valuation
Price to earnings (TTM)
24.988
Price to revenue (TTM)
2.616
Price to book
1.62
Price to tangible book (TTM)
-9.84
Price to free cash flow (TTM)
17.809
Free cash flow yield (TTM)
5.61%
Free cash flow per share (TTM)
5.766
Dividend yield (TTM)
0.93%
Forward dividend yield
0.93%
Growth
Revenue change (TTM)
4.11%
Earnings per share change (TTM)
-14.33%
3-year revenue growth (CAGR)
4.28%
10-year revenue growth (CAGR)
5.40%
3-year earnings per share growth (CAGR)
55.53%
10-year earnings per share growth (CAGR)
8.00%
10-year dividend per share growth (CAGR)
0.87%
What the Analysts think about Zimmer Biomet
Analyst ratings (Buy, Hold, Sell) for Zimmer Biomet stock.
Bulls say / Bears say
Zimmer Biomet reported Q2 2025 revenue of $2.08 billion, up 7% year-over-year, and adjusted EPS of $2.07, both beating consensus estimates and driven by strong hip and knee demand. (Reuters)
The company raised its full-year 2025 adjusted EPS guidance to $8.10-$8.30 and expects revenue growth of 6.7%-7.7%, reflecting confidence in continued market momentum. (Reuters)
The July 2025 acquisition of Monogram Technologies for $177 million bolsters Zimmer Biomet’s ROSA robotics platform with AI-powered knee arthroplasty capabilities and is projected to be accretive to EPS in 2028. (Reuters)
In May 2025, Zimmer Biomet lowered its 2025 adjusted profit forecast to $7.90-$8.10 per share, citing acquisition integration costs, proposed tariffs, and currency fluctuations, signaling near-term earnings pressure. (Reuters)
The anticipated impact of proposed U.S. tariffs on import materials is estimated at $60 million-$80 million in operating profit headwinds for 2025, highlighting policy-driven margin risks. (Reuters)
The Monogram Technologies transaction is expected to be neutral to adjusted EPS through 2027, delaying any accretive benefit until at least 2028 and offering limited near-term financial upside. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Zimmer Biomet Financial Performance
Revenues and expenses
Zimmer Biomet Earnings Performance
Company profitability
Zimmer Biomet News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zimmer Biomet stock?
Zimmer Biomet (ZBH) has a market cap of $20B as of October 22, 2025.
What is the P/E ratio for Zimmer Biomet stock?
The price to earnings (P/E) ratio for Zimmer Biomet (ZBH) stock is 24.99 as of October 22, 2025.
Does Zimmer Biomet stock pay dividends?
Yes, the Zimmer Biomet (ZBH) stock pays dividends to shareholders. As of October 22, 2025, the dividend rate is $0.96 and the yield is 0.93%. Zimmer Biomet has a payout ratio of 23.38% on a trailing twelve-month basis.
When is the next Zimmer Biomet dividend payment date?
The next Zimmer Biomet (ZBH) dividend payment date is unconfirmed.
What is the beta indicator for Zimmer Biomet?
Zimmer Biomet (ZBH) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.